

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653cmk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	Feb 24 PCTGEN now available on STN
NEWS	4	Feb 24 TEMA now available on STN
NEWS	5	Feb 26 NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26 PCTFULL now contains images
NEWS	7	Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24 PATDPAFULL now available on STN
NEWS	9	Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11 Display formats in DGENE enhanced
NEWS	11	Apr 14 MEDLINE Reload
NEWS	12	Apr 17 Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28 RDISCLOSURE now available on STN
NEWS	16	May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19 Simultaneous left and right truncation added to WSCA
NEWS	20	May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06 Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06 PASCAL enhanced with additional data
NEWS	23	Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25 HSDB has been reloaded
NEWS	25	Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21 Identification of STN records implemented
NEWS	27	Jul 21 Polymer class term count added to REGISTRY
NEWS	28	Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS EXPRESS		April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:57:51 ON 29 JUL 2003

```
=> file medline caplus biosis embase scisearch agricola
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                      ENTRY      SESSION
FULL ESTIMATED COST                  0.21          0.21
```

FILE 'MEDLINE' ENTERED AT 16:58:15 ON 29 JUL 2003

FILE 'CAPLUS' ENTERED AT 16:58:15 ON 29 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:58:15 ON 29 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 16:58:15 ON 29 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:58:15 ON 29 JUL 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 16:58:15 ON 29 JUL 2003

```
=> s galectin-3
L1      2359 GALECTIN-3
```

```
=> s l1 (p) inhibit?
L2      541 L1 (P) INHIBIT?
```

```
=> s (glomerular nephritis) or (diabetic nephropathy) or (tissue fibrosis)
L3      40221 (GLOMERULAR NEPHRITIS) OR (DIABETIC NEPHROPATHY) OR (TISSUE
          FIBROSIS)
```

```
=> s extracellular matrix
L4      164823 EXTRACELLULAR MATRIX
```

```
=> s l3 (p) l4
L5      1270 L3 (P) L4
```

```
=> s l5 (p0 l1
MISSING OPERATOR 'L35 (P0'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
```

```
=> s l5 (p) l1
L6      2 L5 (P) L1
```

```
=> duplicate remove l6
PROCESSING COMPLETED FOR L6
L7      2 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)
```

```
=> d l7 1-2 ibib abs
```

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:179383 CAPLUS
TITLE: N.epsilon.-(carboxymethyl)lysine-induced mesangial cell
activation
AUTHOR(S): Lim, Hyun Jin; Song, Jaesook; Ha, Hunjoo; Lee, Hi Bahl

CORPORATE SOURCE: Department of Internal Medicine, Hyonam Kidney Laboratory, College of Medicine, Soon Chun Hyang University, Seoul, S. Korea

SOURCE: Taehan Sinjang Hakhoechi (2002), 21(1), 20-28
CODEN: TSHACY; ISSN: 1225-0015

PUBLISHER: Korean Society of Nephrology

DOCUMENT TYPE: Journal

LANGUAGE: Korean

AB Background: Advanced glycation end products (AGE) are independent risk factors in the development and progression of **diabetic nephropathy**. Receptor for AGE(RAGE) is considered the main receptor involved in AGE-induced cell activation. **Galectin-3**, another AGE receptor, has recently been found up-regulated in mesangial cells(MC) cultured under high glucose and in diabetic rat kidneys. N.epsilon.-(carboxymethyl)lysine(CML) is a well characterized AGE but its role in MC activation is unknown. The present study examd. the effects of CML on MC proliferation and **extracellular matrix**(ECM) secretion. Methods: Synchronized rat MC were stimulated with different concns. of CML-bovine serum albumin(BSA), control BSA, and transforming growth factor-.beta.1(TGF-.beta.1) for up to 72 h. Cell proliferation was measured by [3H]-thymidine incorporation. Fibronectin, TGF-.beta.1, plasminogen activator inhibitor(PAI)-1 secreted into the media and RAGE and **galectin-3** expression in MC were measured by Western blot anal. and ELISA Results: 1,000 .mu.g/mL of CML-BSA decreased [3H]-thymidine incorporation by MC at 48 h and 10 ng/mL TGF-.beta.1 at 24 and 48 h. CML-BSA 100 and 1,000 pg/mL, control BSA 1,000 pg/mL, and TGF 8 10 ng/mL increased fibronectin secretion at 48 h CML-BSA up to 1,000 pg/mL did not affect TGF B1 or PAI-1 secretion. TGF-.beta.1 10 ng/mL, however, significantly increased PAI-1 secretion. Cultured MC expressed both RAGE and galec- tin-3. CML-BSA 100 .mu.g/mL upregulated **galectin-3** expression. Conclusion: CML-BSA decreased MC proliferation and increased fibronectin secretion, suggesting that CML may lead to ECM accumulation and glomerulosclerosis in diabetic animals. MC express RAGE and **galectin-3** constitutively and CML-induced **galectin-3** upregulation may have a role in AGE-induced MC activation.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:116925 CAPLUS

DOCUMENT NUMBER: 132:165131

TITLE: Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix

INVENTOR(S): Sasaki, Satoshi; Sumi, Yoshihiko; Hughes, Reginald Colin

PATENT ASSIGNEE(S): Teijin Limited, Japan

SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007624	A2	20000217	WO 1999-JP4238	19990805
WO 2000007624	A3	20000622		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,			

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9950653 A1 20000228 AU 1999-50653 19990805
 EP 1104307 A2 20010606 EP 1999-935073 19990805
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002522398 T2 20020723 JP 2000-563306 19990805
 PRIORITY APPLN. INFO.: JP 1998-233499 A 19980806
 WO 1999-JP4238 W 19990805
 AB A pharmaceutical compn. having an inhibitory effect on the overprodn. and
 the accumulation of **extracellular matrix**, said compn.
 comprising as an active ingredient a compd. that inhibits the biol.
 activity of **galectin-3**, which pharmaceutical compn.
 can serve as a therapeutic or preventive agent for **glomerular
 nephritis, diabetic nephropathy or
 tissue fibrosis**, as well as the use of said compd. for
 the prodn. of pharmaceuticals for the above-mentioned use, and a method
 for inhibition of the overprodn. and accumulation of the
extracellular matrix.

=> d his

(FILE 'HOME' ENTERED AT 16:57:51 ON 29 JUL 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
 16:58:15 ON 29 JUL 2003

L1 2359 S GALECTIN-3
 L2 541 S L1 (P) INHIBIT?
 L3 40221 S (GLOMERULAR NEPHRITIS) OR (DIABETIC NEPHROPATHY) OR (TISSUE F
 L4 164823 S EXTRACELLULAR MATRIX
 L5 1270 S L3 (P) L4
 L6 2 S L5 (P) L1
 L7 2 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)

=> s 15 (p) 12

L8 2 L5 (P) L2

=> s 18 not 17

L9 0 L8 NOT L7

=> s mesangium cell

L10 3549 MESANGIUM CELL

=> s 13 (p) 110

L11 5 L3 (P) L10

=> s 111 (p) 11

L12 0 L11 (P) L1

=> s sasaki satoshi/au

L13 582 SASAKI SATOSHI/AU

=> s sumi yoshihiko/au

L14 40 SUMI YOSHIHIKO/AU

=> s hughes reginald/au

L15 0 HUGHES REGINALD/AU

=> s (l13 or l14) and 11

L16 3 (L13 OR L14) AND L1

=> duplicate remove 116

DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L16

L17 2 DUPLICATE REMOVE L16 (1 DUPLICATE REMOVED)

=> s l17 not l7

L18 1 L17 NOT L7

=> d l18 1 ibib abs

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:221704 CAPLUS

DOCUMENT NUMBER: 131:57362

TITLE: **Galectin-3** modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies

AUTHOR(S): **Sasaki, Satoshi**; Bao, Qi; Hughes, R. Colin

CORPORATE SOURCE: National Institute for Medical Research, London, NW7 1AA, UK

SOURCE: Journal of Pathology (1999), 187(4), 481-489

CODEN: JPTLAS; ISSN: 0022-3417

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Galectin-3** is a .beta.-galactoside-binding protein synthesized by macrophages and other inflammatory cells and expressed in various branching epithelia, including the developing kidney. The expression of **galectin-3** has been studied in a rat model of acute mesangial proliferative glomerulonephritis in which a single injection of anti-Thy1.1 antibodies leads to destruction of mesangial cells expressing a Thy1.1 epitope on their surface. The glomerular lesion is characterized by expansion of the mesangial matrix, esp. laminin and collagen type IV, and mesangial hypercellularity. **Galectin-3** expression, which is sparse in mature rat kidney and confined to the apical face of some distal tubules, is increased within 1-3 days following antibody administration, with the recruitment of glomerular macrophages and pronounced neo-expression in the cytoplasm and at the basal face of distal tubules. At later times, **galectin-3** is detected immunohistochem. in the repopulating mesangial cell mass, preceding the extensive mesangial deposition of laminin and collagen type IV. Mesangial cells in culture do not produce appreciable amts. of **galectin-3** but do bind and endocytose exogenously added lectin. Addn. of **galectin-3** to primary cultures of mesangial cells prepd. from normal rats induces a 1.cntdot.5-fold increase in the synthesis of collagen type IV and it also acts in synergy with a quant. similar stimulatory effect of transforming growth factor .beta. (TGF-.beta.) on matrix synthesis. Exogenous **galectin-3** prolongs the survival of mesangial cells in serum-free cultures and also protects these cells against cytotoxic effects of TGF-.beta.. The data support the notion that the increased expression and secretion of **galectin-3** in infiltrating macrophages and in distal tubular epithelia, together with up-regulation of IL-1.beta. and TGF-.beta. genes, play a role in mesangial hypercellularity in the progression of one model of inflammatory renal disease.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:57:51 ON 29 JUL 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:58:15 ON 29 JUL 2003

L1 2359 S GALECTIN-3

L2 541 S L1 (P) INHIBIT?

L3 40221 S (GLOMERULAR NEPHRITIS) OR (DIABETIC NEPHROPATHY) OR (TISSUE F
 L4 164823 S EXTRACELLULAR MATRIX
 L5 1270 S L3 (P) L4
 L6 2 S L5 (P) L1
 L7 2 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)
 L8 2 S L5 (P) L2
 L9 0 S L8 NOT L7
 L10 3549 S MESANGIUM CELL
 L11 5 S L3 (P) L10
 L12 0 S L11 (P) L1
 L13 582 S SASAKI SATOSHI/AU
 L14 40 S SUMI YOSHIHIKO/AU
 L15 0 S HUGHES REGINALD/AU
 L16 3 S (L13 OR L14) AND L1
 L17 2 DUPLICATE REMOVE L16 (1 DUPLICATE REMOVED)
 L18 1 S L17 NOT L7

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	51.91	52.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

FILE 'REGISTRY' ENTERED AT 17:10:29 ON 29 JUL 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JUL 2003 HIGHEST RN 556740-18-2
 DICTIONARY FILE UPDATES: 28 JUL 2003 HIGHEST RN 556740-18-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=> s pirfenidone

L19 1 PIRFENIDONE

=> d l19

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 53179-13-8 REGISTRY
 CN 2(1H)-Pyridinone, 5-methyl-1-phenyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 5-Methyl-1-phenyl-2(1H)-pyridinone
 CN 5-Methyl-1-phenyl-2(1H)-pyridone
 CN AMR 69
 CN **Pirfenidone**
 FS 3D CONCORD
 MF C12 H11 N O
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS,

BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN,
 DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

71 REFERENCES IN FILE CA (1947 TO DATE)
 71 REFERENCES IN FILE CAPLUS (1947 TO DATE)

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.30	58.42
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.95

STN INTERNATIONAL LOGOFF AT 17:11:05 ON 29 JUL 2003



Creation date: 02-06-2004
Indexing Officer: KHALL - KIM HALL
Team: OIPEBackFileIndexing
Dossier: 09744328

Legal Date: 07-30-2003

No.	Doccode	Number of pages
1	CTFR	11
2	1449	1
3	1449	1

Total number of pages: 13

Remarks:

Order of re-scan issued on